EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitNetzwerk-Metaanalyse

Comparative assessment of efficacy and safety of ambrisentan and bosentan in patients with pulmonary arterial hypertension: A meta‐analysis

Qinhua Zhao, Na Guo, Jun Chen, Daniel Parks, Zhuang Tian iD

Journal of Clinical Pharmacy and Therapeutics · 2022-02 · 47 (2) · 146-156

DOI: 10.1111/jcpt.13481 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Clinical Pharmacy and Therapeutics, online erschienen am 28.07.2021. Verfasst von Qinhua Zhao und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary Circulation, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 57 Literaturangaben. Gefördert von: GlaxoSmithKline (China) R&D Company Limited.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antihypertensive AgentsBosentanEndothelin Receptor AntagonistsHumansLiver Function TestsPhenylpropionatesPulmonary Arterial HypertensionPyridazinesRandomized Controlled Trials as TopicWalk Test

Stichwörter der Autor:innen

6-min walk distanceBorg dyspnoea indexliver dysfunctionnetwork meta-analysisrandomized controlled trials

Substanzen

Antihypertensive AgentsEndothelin Receptor AntagonistsPhenylpropionatesPyridazinesambrisentanBosentan

Autor:innen und Institutionen

  • Department of Pulmonary Circulation, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China.
  • GlaxoSmithKline, Beijing, China.
  • GlaxoSmithKline, Collegeville, PA, USA.
  • Department of Cardiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

ORCID-Profile: Zhuang Tian

Förderung

  • GlaxoSmithKline (China) R&D Company Limited

Zitieren

APA

Zhao, Q., Guo, N., Chen, J., Parks, D., & Tian, Z. (2022). Comparative assessment of efficacy and safety of ambrisentan and bosentan in patients with pulmonary arterial hypertension: A meta‐analysis. Journal of Clinical Pharmacy and Therapeutics, 47(2), 146-156. https://doi.org/10.1111/jcpt.13481

Vancouver

Zhao Q, Guo N, Chen J, Parks D, Tian Z. Comparative assessment of efficacy and safety of ambrisentan and bosentan in patients with pulmonary arterial hypertension: A meta‐analysis. Journal of Clinical Pharmacy and Therapeutics. 2022;47(2):146-156. doi:10.1111/jcpt.13481

BibTeX
@article{Zhao2022,
  author = {Zhao, Qinhua and Guo, Na and Chen, Jun and Parks, Daniel and Tian, Zhuang},
  title = {Comparative assessment of efficacy and safety of ambrisentan and bosentan in patients with pulmonary arterial hypertension: A meta‐analysis},
  journal = {Journal of Clinical Pharmacy and Therapeutics},
  year = {2022},
  volume = {47},
  number = {2},
  pages = {146--156},
  doi = {10.1111/jcpt.13481}
}
Kostenlos starten →